Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.67 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.67 |
| ▸ | NAT1 | P18440 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438513 | 1.00 | MTOR (1.00) | MTORRPTORMLST8NAT1PDE4B | |
| SCHEMBL23036935 | 0.89 | MTOR (0.80) | MTORRPTORMLST8PDE4BMEN1 | |
| SCHEMBL30438310 | 0.89 | MTOR (0.80) | MTORRPTORMLST8PDE4BMEN1 | |
| SCHEMBL30437715 | 0.84 | MTOR (1.00) | MTORRPTORMLST8NAT1CISD1 | |
| SCHEMBL23036890 | 0.84 | MTOR (1.00) | MTORRPTORMLST8NAT1 | |
| SCHEMBL30438520 | 0.84 | MTOR (1.00) | MTORRPTORMLST8NAT1 | |
| SCHEMBL23036897 | 0.84 | MTOR (1.00) | MTORRPTORMLST8NAT1CISD1 | |
| SCHEMBL23036906 | 0.81 | MTOR (1.00) | MTORRPTORMLST8NAT1CISD1 | |
| SCHEMBL29249414 | 0.79 | MTOR (0.65) | MTORRPTORMLST8MEN1ALDH1A1 | |
| SCHEMBL23036884 | 0.77 | MTOR (1.00) | MTORRPTORMLST8NAT1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | claimed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | claimed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | claimed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | claimed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | claimed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.